Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The ...
FierceBiotech1d
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment ...
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that ...
Yahoo Finance5d
BiocureTechInc (CURE-X.CN)
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target ...
Investing14d
Black Diamond shares target reiterated, overweight rating on recent updates
These results are seen as setting benchmarks for Black Diamond's BDTX-1535, particularly in its ongoing first-line non-classical cohort. The targeted outcomes for BDTX-1535 include an objective ...
Investing14d
Black Diamond shares target reiterated, overweight rating on recent updates
These results are seen as setting benchmarks for Black Diamond's BDTX-1535, particularly in its ongoing first-line non-classical cohort. The targeted outcomes for BDTX-1535 include an objective ...
Investing25d
Versant Venture Capital VI sells $1.4m in Black Diamond Therapeutics stock
Piper Sandler reiterated its Overweight rating on the company, maintaining a $12.00 price target, emphasizing the potential of BDTX-1535 in the treatment of EGFR NSCLC. The company sees potential for ...
Investing25d
Versant Venture Capital VI sells $1.4m in Black Diamond Therapeutics stock
Piper Sandler reiterated its Overweight rating on the company, maintaining a $12.00 price target, emphasizing the potential of BDTX-1535 in the treatment of EGFR NSCLC. The company sees potential ...